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manchester.ac.ukAbstractRecombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults
has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that
‘for approved indications, GH is safe’; however, the statement highlighted a number of areas for on-going surveillance of
long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH
treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard
to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults whoicensed under a Creative Commons
.0 Unported License.
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Position Statement D B Allen and others GH safety workshop report 174 :2 P2were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric
Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of
rhGH. The ouput of the meeting is a concise position statement.www.eje-online.orgEuropean Journal of
Endocrinology
(2016) 174, P1–P9IntroductionRecombinant human growth hormone (rhGH) has been in
use for 30 years, and over that time its safety and efficacy
in children and adults has been subject to considerable
scrutiny. Prior to 1985, cadaveric pituitary-derived GH was
used, but this was stopped in most countries that year,
following the recognition that it could transmit Creutz-
feldt–Jakob disease, with patients still being diagnosed
after incubation periods upto 40 years (1). In 2001, a
statement from the GH Research Society (GRS) concluded
that ‘for approved indications, rhGH is safe’ (2); however,
the statement highlighted a number of areas for on-going
surveillance of long-term safety, including cancer risk,
impact on glucose homeostasis, and use of high dose
pharmacological rhGH treatment. Over the intervening
years, there have been a number of publications addres-
sing the safety of rhGH with regard to mortality, cancer
and cardiovascular risk, and the need for long-term
surveillance of the increasing number of adults who were
treated with rhGH in childhood.
Against this backdrop of interest in safety, the
European Society of Paediatric Endocrinology (ESPE), the
GRS, and the Pediatric Endocrine Society (PES) convened
a meeting to reappraise the safety of rhGH. Invitees
included pediatric and adult endocrinologists, epidemiol-
ogists, and medical/safety representatives from the
pharmaceutical industry, with the latter being asked to
share data regarding safety from their own databases.
Review papers (including meta-analyses of safety data)
were written in preparation for the meeting (3, 4), and all
participants were provided in advance with the key
literature, which formed the basis for the group discus-
sions (see Supplemental References, see section on
supplementary data given at the end of this article). The
quality of the evidence from the literature was not
formally graded as there are no randomized controlled
trials on safety issues and a significant amount of the
safety literature during GH treatment years is derived from
post marketing surveillance studies. A planning commit-
tee of academic pediatric and adult endocrinologists chosethe topics, designed the program, and formulated the
questions for discussion in break-out groups (Supple-
mental Data: Meeting Program).
Break-out group reports were discussed in plenary
sessions aimed at generating the majority view on the
responses to the questions posed at the workshop. Writing
groups at the end of days 1 and 2 of the meeting compiled
their reports, and these were brought together into a final
statement that was shared with and revised by participants
on the last day, edited further, and sent for final review
after the meeting. When no agreement was reached on
specific points, a majority vote was taken; when there was
no majority, there was further discussion, rewording of
the document, and the vote was repeated until a majority
opinion was obtained. Representatives from medical/
safety departments of pharmaceutical companies partici-
pated in the discussions and presented data during the first
2 days. They were not present during the writing and
voting process on the last day. However, they were asked
to review the manuscript for factual errors about their data
after completion of the final draft.
The text of this statement was based on: i) the
combined comments of the break-out groups to the
questions, ii) the combined comments of the whole
group during plenary discussions, iii) knowledge of the
current literature, and iv) the combined experience of
clinicians and scientists active in the GH field. This report
is not intended to be an exhaustive review of the literature,
but is a concise report of the proceedings of the workshop.Mortality and cancer risk
In evaluating the available evidence addressing
mortality and cancer risk among GH-treated populations,
critical assessment of the strengths and limitations of
published research and safety data presented within the
meeting was undertaken. Features related to limitations in
the quality, and thus interpretation of these data, are
highlighted below.
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Position Statement D B Allen and others GH safety workshop report 174 :2 P3Overall mortality and GH treatment
The group recognized that many of the disorders treated
with GH in children and adults have an inherently higher
mortality risk, which is related to the underlying disorder.
In most studies therefore the potential impact of GH
treatment on overall mortality is difficult to distinguish
from the impact of the underlying disorder. This was also
the conclusion reached on neoplasia risk in GH-treated
children published after the workshop (5).
The agreement reached was that aggregate evidence
from available datasets does not support an association
between ongoing or previous GH therapy and all-cause
mortality. The group acknowledged that some individual
reports and meta-analyses had indicated association (3).
However, major concern was raised about lack of
appropriate comparison cohorts of untreated patients,
incomplete data on GH exposure and treatment regimens,
inadequate characterization of patients, and inadequate
identification of other risk factors. In particular, problems
with duration and completeness of follow-up, study
designs used to date, and reported risk metrics make it
difficult to reach definitive conclusions about a causal
relationship between GH treatment and all-cause
mortality. It is also necessary to distinguish relative risk
and the standardized mortality ratio from other metrics
such as absolute risk and number-needed-to-harm, with
the latter being more relevant to counseling patients and
families about risk (Table 1).
The ongoing multicenter ‘Safety and Appropriateness
of Growth hormone treatments in Europe’ (SAGhE)
study, which is assessing mortality in adults previously
treated with rhGH in childhood for approved indications,
will add further information to this field. A full
description of the cohort and the methodologies that
are being used to assess mortality and cancer incidenceTable 1 Terms and their definitions used to quantify risk.
Relative risk is based on a comparison of the risk in GH treated
patients, or a subset of such patients, vs the risk in an
untreated comparison group or population
The standardized mortality ratio (SMR) is the ratio of observed
cases among GH treated patients, or a subset of such patients,
to the expected number of cases based upon the general
population rate
The absolute risk is the calculated rate, generally expressed as
number of cases per 1000, 10 000, or 100 000 person years
The number-needed-to-harm is defined as the number of
patients needed to be exposed to a risk factor over a specified
period to cause harm in one patientrisks is provided in Swerdlow et al. (published after the
workshop was held) (6).Cause specific mortality and GH treatment
The group agreed that available data are inadequate for
reaching conclusions regarding any influence of GH on
cause-specific mortality. As noted above for all-cause
mortality, the key question in assessing the potential
impact of GH treatment on subsequent mortality concerns
the contribution of GH deficiency itself to mortality risk. It
is generally accepted that adult GH deficiency and certain
short-stature syndromes are associated with elevated
mortality in the untreated state. However, cause-specific
mortality rates for persons with these disorders who are
not treated with GH have not been quantified precisely
enough to allow comparison with GH-treated patients.Risk of new primary cancers
Available data in children do not indicate an increased risk
of new primary cancers in GH recipients (Table 2). The data
for new cancer risk in adult GH recipients are reassuring
(Table 2). However, there are limitations to all these
statements. A variety of information sources are available
in relation to cancer risk among GH-treated patients,
including post-marketing surveillance (phase 4) studies, a
limited number of other cohort studies, and clinical series.
While some of these data sources are large and include
many patient years of observation with generally reassur-
ing results, the number of subjects with long duration of
follow-up is small and data are incomplete, precluding
definitive long-term safety conclusions. Other weaknesses
are insufficient control for selection bias, inadequate
sample sizes to assess cancers with low incidence, and
lack of appropriate comparison populations.
The group did not support cancer surveillance beyond
local standard practice in patients (children and adults)
currently treated with GH nor in those previously treated
with GH (including those with a previous malignancy).Risk of recurrence of a previous primary cancer
Available data in children do not indicate an increased risk
of recurrence of primary cancer in GH recipients (Table 2).
The data in adult GH recipients are presently insufficient
to address this situation, but available data on benign
pituitary tumors do not indicate an increased risk of
recurrence during long-term GH replacement (4) (Table 2).www.eje-online.org
Table 2 Majority view of the effect of GH treatment for approved indications on cancer risk in children and adults (including those
with a childhood-onset of GH deficiency). The term ‘robust’ is used when there are multiple independent published sources
supporting the statement (see Supplemental References). The term ‘suggestive’ is used when there are less than three sources
supporting the statement. The term ‘insufficient’ is used when available publications provide inadequate evidence to support the
statement.
Age at onset of
GH treatment New primary cancer
Recurrence of the primary
cancer in survivors
Second or subsequent
neoplasm in survivors
Child No evidence for GH treatment
effect Level: robust
No evidence for GH treatment
effect Level: robust
Risk present but diminishes with time
from onset of GH treatment Level:
suggestive
Adult No evidence for GH treatment
effect Level: suggestive
Insufficient data available Insufficient data available
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Position Statement D B Allen and others GH safety workshop report 174 :2 P4Risk of second or subsequent neoplasms
The risk of second primary tumors in GH-treated survivors
of pediatric cancers was reported to be elevated in one
study population, with highest risk early after GH
treatment and declining with longer follow-up (7, 8, 9).
The general opinion was that the association between
GH therapy and risk of second tumors is insufficient to
preclude use of rhGH for licensed indications in children
(Table 2). Data are insufficient in patients surviving
adult-onset malignancies to reach a conclusion about
safety of GH use in this population (Table 2). It is
recommended that potential risk be discussed with
patients and their families.Initiation of GH therapy after cancer treatment
Few data are available to provide guidance on the
appropriate interval between completion of cancer
therapy and initiation of GH treatment in both children
and adults. Therefore in deciding on this interval,
consideration should be given to factors related to the
tumor, time elapsed since completion of cancer treatment,
and the importance of initiating GH treatment in the
individual patient (e.g. severity of growth failure if not
treated with GH).Use of GH therapy in patients with a background risk
for cancer
Definitive data are lacking regarding the safety of GH
therapy in ‘high risk’ patients (in particular children),
including those with syndromes, diseases, and mutations
known to be associated with an inherent elevated risk for
cancer and early mortality (e.g. Neurofibromatosis type 1,
Fanconi anaemia, or Down syndrome). Therefore, thewww.eje-online.orgdecision to start GH therapy should be carefully
considered and discussed with families.Stroke, cardiovascular disease,
and metabolic risk
Stroke
There was agreement that data were inadequate to
determine whether GH therapy in childhood increases
risk of stroke in young adults. The rationale for reaching
this conclusion was that in the one published study
reporting an association (10), the number of subjects was
small and the risk of developing this complication in a
comparable population was unknown. This single study
reported 11 validated cases of stroke, including subar-
achnoid hemorrhage, intracerebral hemorrhage, and
ischemic stroke at a mean age of 24G7 years, out of a
population of 6874 patients with either isolated idiopathic
GH deficiency or short stature in those born small for
gestational age (SGA), or idiopathic short stature (ISS),
who started treatment with rhGH between 1985 and 1996.
Absolute risk of stroke was still small in this population
(1.6/1000 persons) and there may have been potential
confounding factors; data were lacking on family history,
concomitant medications, smoking, or hypertension.
Stroke is a potential serious complication that warrants
further scrutiny, but at present the evidence is insufficient
to raise stroke as a concern with families before starting
GH treatment in children.Cardiovascular disease and metabolic risk
Multiple studies have analyzed the effects of GH therapy
on risk factors for cardiovascular and metabolic disease.
Administration of GH modulates insulin sensitivity in a
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Position Statement D B Allen and others GH safety workshop report 174 :2 P5complex manner influenced by numerous factors such as
age, body composition, and duration of therapy. The
incidence of developing glucose intolerance or overt type
2 diabetes mellitus (T2D) during GH treatment in pediatric
patients with GH deficiency or ISS is very low (11).
Although the lifetime risk of glucose intolerance and
T2D in a number of conditions treated with GH, including
Turner syndrome (TS) and in short children born SGA, is
higher than in the background population, GH treatment
does not increase the incidence of T2D in these conditions
in the short term.
In a subset of adult GHD patients with a propensity
toward development of T2D, such as obesity and/or family
history of T2D, GH therapy can be associated with the
development of glucose intolerance or T2D in the first year
of therapy (4), so monitoring with HbA1c is important.
GH reduces visceral fat and leads to an increase in lean
body mass. Cardiovascular risk markers are increased in
children and adults with GHD; these can improve with
administration of GH. GH has also been shown to reduce
LDL cholesterol, and there is a suggestion that GH can
increase HDL cholesterol and reduce carotid intimal
thickness; however, it has not been clearly demonstrated
that GH replacement decreases the rate of cardiovascular
events (4).
There is no increase in blood pressure (BP) in children
or adults on GH therapy. In fact there is a modest
reduction in diastolic BP with GH administration in
short SGA children and in adults with GHD.Managing recognized side-effects
The side-effects described below may be related to the use
of GH. They can occur independent of GH and the role of
GH should be considered on an individual basis.
Intracranial hypertension
Intracranial hypertension (ICH) may occur secondary to
GH therapy in children, but can be difficult to confirm.
The absence of papilledema does not exclude the
diagnosis. Symptoms resolve with discontinuation of
GH, which then can be restarted at a lower dose and
gradually increased. Persistent severe headaches that do
not resolve with discontinuation of GH therapy should be
further evaluated by a neurologist.
Musculoskeletal symptoms
In adults, edema, carpal tunnel syndrome, and muscu-
loskeletal aches and pains related to fluid retention may bea sign of GH over-dosage. These symptoms rarely occur
in adults if GH is started at a low dose and titrated up.
In children, musculoskeletal aches may be related to
increased growth velocity or underlying conditions rather
than the GH treatment.Scoliosis
Scoliosis is more prevalent in patients with TS or Prader–
Willi syndrome (PWS) even in the absence of GH
treatment. Progression of scoliosis can be accelerated by
rapid growth, such as the pubertal growth spurt, and is not
associated with GH treatment per se. Clinical examination
of the spine should be occur before start of therapy and at
follow-up of pediatric patients receiving GH therapy. Even
in the presence of scoliosis, GH therapy can be initiated
or continued, though radiographic studies should be
obtained to monitor for any change.Slipped capital femoral epiphysis
Slipped capital femoral epiphysis has been associated with
GH therapy in children and is likely due both to growth
acceleration and the underlying condition. Radiographic
studies and appropriate referral are urgently required.Obstructive sleep apnea
GH can stimulate adenotonsillar growth and may thereby
exacerbate obstructive sleep apnea, particularly in patients
receiving GH treatment for PWS. Polysomnography prior
to initiating therapy and monitoring during GH treatment
is recommended for patients with PWS (12). Occurence of
obstructive sleep apnea is also increased in obese adults
with GHD and if exacerbated with GH treatment, a dose
reduction should be considered.Pancreatitis
Pancreatitis has been observed to occur in children
receiving GH therapy. While this side-effect is listed on
the package insert, it is extremely rare and its causal
relationship to GH treatment remains unclear. However,
if a child on GH therapy develops severe abdominal pain,
pancreatitis should be considered.Alterations in cortisol and thyroid metabolism with
GH treatment
GH increases the tissue conversion of active cortisol to
inactive cortisone. Thus, initiation of GH therapy inwww.eje-online.org
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Position Statement D B Allen and others GH safety workshop report 174 :2 P6patients with subclinical adrenocorticotropic hormone
deficiency may induce symptomatic adrenal insufficiency
requiring glucocorticoid substitution, and patients already
on cortisol replacement may need dose adjustment.
GH increases the peripheral conversion of thyroxine
(T4) to tri-iodothyronine. Commencement of GH replace-
ment may therefore unmask pre-existing central
hypothyroidism as defined by a fall of serum-free T4 into
the subnormal range. In patients with hypopituitarism
already taking T4, adjustment of the T4 dose may be
needed after initiation of GH replacement therapy if a
decrease in the serum concentration of free T4 occurs.
Thyroid function should therefore be monitored at
initiation of GH treatment and after dose increases.
For children with isolated, idiopathic GHD without
hypothyroidism and no abnormality on magnetic reso-
nance imaging (MRI) of the hypothalamic–pituitary
region, routine evaluation of adrenal function is not
required unless symptoms develop. For patients of any age
with reason for concern regarding evolving pituitary
hormone deficiencies, such as following irradiation or
mutations associated with evolving hypopituitarism,
the hypothalamic–pituitary–adrenal and –thyroid axes
should be evaluated regularly.Dosing and monitoring of GH therapy
Risk reduction: pediatric patients
Baseline clinical evaluation should be conducted based
on the condition prompting GH treatment. For example,
full pituitary function testing and MRI of the brain, with
special attention to the hypothalamic–pituitary region, are
indicated in children with GH deficiency. The primary
objective of GH therapy in children is to obtain a satis-
factory growth response without incurring adverse events.
Measurement of insulin-like growth factor 1 (IGF1)
concentration is recommended for children with GH defici-
ency treated with GH, with the goal of normalizing serum
IGF1 concentrations. However, the group recognized the
lack of evidence base supporting the value of IGF1 moni-
toring for safety inchildrenandthe lackofanydata to indicate
a safe upper limit for serum IGF1 concentrations. Some
epidemiological studies in healthy adults without GHD have
suggested associations between serum IGF1 concentrations
in the upper part of the normal range or above and some
forms of cancer, and between serum IGF1 concentrations in
the lower part of the normal range and cardiovascular disease.
The relevance of such studies for pediatric patients or GHD
adults treated with GH has not been established.www.eje-online.orgWhen the growth response is not satisfactory in
children with TS, short children born with SGA, and
those with chronic renal insufficiency, the GH dose can be
increased within the recommended range in order to
achieve the desired growth response. This can lead to IGF1
concentrations above the normal range (OC2 SDS). There
is no clinical evidence at this time in children that raising
the IGF1 into this higher range for a period of time carries
an increased risk of adverse events. However, this situation
has not been rigorously evaluated and aiming for IGF1
levels in the normal range is recommended.
Monitoring of GH treatment should include: bone age
assessment, thyroid function testing (in GH-deficient
patients), and as indicated above, adrenal function testing
in patients with evidence or suspicion of multiple
pituitary hormone deficiency (e.g. transcription factor
defects, midline abnormalities). Additional general safety
monitoring for non-GH deficient patients should include
clinical assessment for scoliosis and monitoring of HbA1c
levels (for further details in specific conditions refer to
published reports) (12, 13, 14, 15).
Following completion of linear growth, GH deficiency
should be re-evaluated during the transition period (16, 17).
When ongoing GH deficiency is diagnosed, we recommend
referral to an adult endocrinologist for consideration of
adult GH replacement.Risk reduction: adult patients
Adult patients with GH deficiency should provide a
detailed medical history, with particular attention to
past or present history and family history of malignancy
and DM, followed by physical examination, pituitary
function testing, and pituitary MRI. Repeat imaging may
not be required in childhood onset GH-deficient patients.
GH replacement is generally initiated with a low dose of
GH and then titrated up based on serum IGF1 concen-
trations and monitoring for fluid retention related
symptoms. The goal is to achieve hormone replacement
with normal age-adjusted serum IGF1 values. Safety
monitoring includes measurement of HbA1c and in
selected patients, additional hormonal testing as discussed
above. Oral estrogen reduces the sensitivity to GH and
therefore any change in oral estrogen use should prompt
IGF1 measurement and re-evaluation of the GH dose.
rhGH is continued in some countries during
pregnancy until about 20 weeks of gestation, after which
time placental GH concentrations are sufficient to
maintain normal serum IGF1 concentrations. In other
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Position Statement D B Allen and others GH safety workshop report 174 :2 P7countries, GH treatment is discontinued when a patient
becomes pregnant.GH treatment during critical illness
GH treatment used at high doses in critically ill patients is
associated with increased mortality (18). There are
however no data on the impact of GH replacement in
GHD patients during critical illness. The group agreed that
GH-deficient children and adults hospitalized with a
critical illness should only be administered GH in
physiologic doses. GH treatment should be stopped in
critically ill patients treated with GH for non-GH deficient
indications because these patients may be receiving
supraphysiological GH doses while retaining endogenous
GH secretion.Table 3 Data limitations related to safety issues.
Insufficient duration and unknown completeness of follow-up
Lack of appropriate comparison populationsOff-label use of GH
The off-label use of GH therapy outside of approved
indications is not endorsed, but it is recognized that GH
is being prescribed for growth promotion in a variety of
conditions with differences between countries. For
example, the use of GH for children with ISS, Noonan
syndrome, SHOX-gene haplo insufficiency, and chronic
renal insufficiency are indications that have been
approved for GH treatment in children in some countries.
For certain other conditions, there is some evidence for
a beneficial effect of GH therapy. These include cystic
fibrosis (CF), inflammatory disorders (e.g. inflammatory
bowel disease, juvenile idiopathic arthritis), and mild
forms of skeletal dysplasia (e.g. hypochondrodysplasia).
The benefit as well as safety profile in these indications has
not been substantiated, and for certain disorders may
involve increased risks (e.g. glucose intolerance in CF, ICH
in hypochondroplasia).
In other situations, GH is prescribed to treat con-
ditions despite lack of substantial scientific evidence for
either efficacy or safety. The group agreed that GH should
not be used ‘off-label’ except in clinical trials that can
assess efficacy and safety or on an approved compassionate
indication protocol. In some countries, it is illegal to
prescribe GH for off-label indications.Lack of complete documentation of GH dose-specific exposure
Lack of dose-specific assessment of IGF1 concentrations
Insufficient control for selection bias
Inconsistent definition and validation of outcomes
Insufficient sample sizes to allow assessment of low incidence
outcomes
Reporting bias and lack of sensitivity to detect more subtle
effectsAbuse of GH
There was full agreement that rhGH should not be
administered for performance enhancement, anti-aging,
or other illicit uses. Toxicity from such interventions is
usually not reported, raising the concern that seriousadverse reactions may occur especially when GH is
combined with other supplements such as anabolic
steroids.Conclusions
Fourteen years after the 2001 GRS consensus statement
(2), the safety record of rhGH remains good, supported
by evidence from the follow-up of thousands of children
and adults over tens of thousands of patient years.
Available information on the safety of GH is derived
from a wide-range of sources from around the world,
which have been of significant value in formulating the
current statement (Supplemental References). Out of
necessity, safety-related issues in GH-treated populations
must rely on results from observational research which
has a greater number of methodological limitations than
randomized placebo-controlled studies (Table 3), with the
latter considered unethical for a therapy that has proven
benefit. After detailed consideration of such limitations,
the group concluded that GH continues to have a good
safety record when used for approved indications and at
recommended doses.
Nevertheless, the group agreed that continued sur-
veillance of those exposed to rhGH is essential both during
and in the years after treatment and into old age in those
who continue therapy. This is particularly important with
the advent of long-acting GH preparations with very
different pharmaco-kinetic and -dynamic profiles
compared to daily rhGH injections.
For future consideration, the group proposed the
establishment of a carefully designed and rigorously
conducted cohort study to provide a single research
resource for testing hypotheses that specifically address
the long-term safety, vascular and metabolic health,
psychosocial, and quality of life outcomes of GH treated
patients. Beyond formal hypothesis testing, a large cohort
would provide opportunities to collect new data fromwww.eje-online.org
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Position Statement D B Allen and others GH safety workshop report 174 :2 P8GH-exposed patients. Any new initiative would need to
incorporate: i) appropriate comparison population(s) to
permit more direct assessment of outcomes between
GH-exposed and non-treated groups; ii) mechanisms for
direct patient contact for longitudinal reporting of health-
related and quality of life outcomes; and iii) ability to
validate selected self-reported outcomes. A comprehensive
cohort study has the potential to contribute substantially
to the knowledge base that informs the clinical care and
long-term management of patients who have received
GH treatment.Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
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